NCT01498484View on ClinicalTrials.gov

Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
EBV-induced LymphomasEBV-associated MalignanciesTransplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
Interventions
BIOLOGICAL

EBV-specific T cells (EBV-CTLs)

EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

Atara Biotherapeutics

INDUSTRY

NCT01498484 - Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies | Biotech Hunter | Biotech Hunter